SEC Tracker
Get the app

CervoMed CRVO

CervoMed reports Q3 2026 financial results

CervoMed (CRVO) filed an 8-K with the SEC on Nov 9, 2026, 4:08 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash position of $19.6 million as of September 30, 2026
  2. 24-week biomarker data from Phase 2a trial in nfvPPA to be presented at CTAD 2026
  3. Phase 2a RESTORE trial for recovery after stroke completed with 45 patients

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when CervoMed files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.